Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.8140 +0.0646 (+8.62%)
Delayed Quote Updated: 12:25 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
News headline image
Coherus BioSciences Earnings Preview ↗
 
Via Benzinga
News headline image
Coherus BioSciences's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
A Preview Of Coherus BioSciences's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
News headline image
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Present at Upcoming Investor Conferences in May
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business' ↗
Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗
 
Via Benzinga
News headline image
PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
FDA Approves UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Present at Upcoming Investor Conferences in March
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
News headline image
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
News headline image
Tesla, NIO And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mixed, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
News headline image
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Junshi Biosciences
Via GlobeNewswire
News headline image
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.